CA Patent

CA2901244A1 — Rasagiline formulations of improved content uniformity

Assigned to Teva Pharmaceutical Industries Ltd · Expires 2006-08-31 · 20y expired

What this patent protects

Disclosed are pharmaceutical preparations of R(+)-N-Propargyl-1-aminoindan salts having enhanced content uniformity, processes for preparation of the compositions, and their uses.

USPTO Abstract

Disclosed are pharmaceutical preparations of R(+)-N-Propargyl-1-aminoindan salts having enhanced content uniformity, processes for preparation of the compositions, and their uses.

Drugs covered by this patent

rasagiline-mesylate (RASAGILINE MESYLATE)

Patent Metadata

Patent number: CA2901244A1
Jurisdiction: CA
Classification: —
Expires: 2006-08-31
Drug substance claim: No
Drug product claim: No
Assignee: Teva Pharmaceutical Industries Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.